Proteomics And Genomics Are Forcing A Re-look At Test Validation Protocol
This article was originally published in The Gray Sheet
Executive Summary
Test developers might need to adjust their approach to assay validation to facilitate adoption of some up-and-coming diagnostic technologies, several speakers suggested at an American Association of Clinical Chemistry meeting Oct. 25 in Washington, D.C
You may also be interested in...
AdvaMed Suggests Firms Should Provide Validated QC Materials To Labs
Manufacturers should be allowed to provide quality control materials for diagnostics to laboratories, AdvaMed says
Multiplex Testing: CDRH Guidance Provokes Array Of Industry Comments
Abbott Labs is urging CDRH to clarify that its April 1draft guidance on multiplex tests for heritable markers, mutations and expression patterns applies only to device submissions
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.